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Abstract: Mycobacterium avium subspecies paratubercu-
losis (MAP) causes a chronic granulomatous inflammation
of the intestines, Johne’s disease, in dairy cows and every
other species of mammal in which it has been identified.
MAP has been identified in the mucosal layer and deeper
bowel wall in patients with Crohn’s disease by methods
other than light microscopy, and by direct visualization in
small numbers by light microscopy. MAP has not been
accepted as the cause of Crohn’s disease in part because
it has not been seen under the microscope in large
numbers in the intestines of patients with Crohn’s disease.
An analysis of the literature on the pathology of Crohn’s
disease and on possible MAP infection in Crohn’s patients
suggests that MAP might directly infect endothelial cells
and adipocytes and cause them to proliferate, causing
focal obstruction within already existing vessels (including
granuloma formation), the development of new vessels
(neoangiogenesis and lymphangiogenesis), and the
‘‘creeping fat’’ of the mesentery that is unique in human
pathology to Crohn’s disease but also occurs in bovine
Johne’s disease. Large numbers of MAP might therefore
be found in the mesentery attached to segments of
intestine affected by Crohn’s disease rather than in the
bowel wall, the blood and lymphatic vessels running
through the mesentery, or the mesenteric fat itself. The
walls of fistulas might result from the neoangiogenesis or
lymphangiogenesis that occurs in the bowel wall in
Crohn’s disease and therefore are also possible sites of
large numbers of MAP. The direct visualization of large
numbers of MAP organisms in the tissues of patients with
Crohn’s disease will help establish that MAP causes
Crohn’s disease.
Mycobacterium avium subspecies paratuberculosis (MAP) causes a
chronic granulomatous inflammation of the intestines in dairy
cows called Johne’s disease. MAP also causes a chronic
inflammation of the intestines in beef cattle and in a wide variety
of other domestic and wild ruminants as well as other mammals,
including nonhuman primates. ‘‘MAP is a specific cause of chronic
inflammation of the intestines in many different ruminants,
including rare species, monogastrics such as dogs and pigs and,
so far, four different types of subhuman primates – macaques,
baboons, gibbon [sic] and cotton-top tamarins’’ [1]. MAP has
been identified in humans with a chronic granulomatous
inflammation of their intestines, Crohn’s disease.
The identification of MAP organisms in patients with Crohn’s
disease has been accomplished by several different techniques.
MAP has been cultured from the intestines [2–4] and blood [5] of
Crohn’s patients. In addition, MAP has been identified in the
intestines [3,4,6–12] and blood [5,11,13] of Crohn’s patients by
PCR amplification of the IS900 DNA sequence specific for MAP.
IS900 PCR also identified MAP in two cervical lymph nodes of a
teenager; 5 years later he developed Crohn’s disease [14].
Antibodies to MAP antigens have been identified in the blood of
Crohn’s patients by ELISA [11,15–17]. DNA in-situ hybridization
has permitted direct visualization by light microscopy of small
numbers of MAP organisms in Crohn’s intestines [12,18–21]. In
2007, in a single study, MAP was directly visualized by light
microscopy in small numbers in Crohn’s intestines using the
traditional Ziehl-Neelsen acid fast stain ([22], Text S1).
While other organisms have also been identified in the intestines
of patients with Crohn’s disease [23], no other putative pathogenic
organism causes a chronic granulomatous inflammation of the
intestines in every other species in which it is present. ‘‘For MAP in
this situation not to contribute to pathogenesis and merely to have
a bystander role, it would be necessary to accept that despite its
specific ability to cause chronic inflammation of the intestine in so
many animals, including primates, it is somehow harmless to
man’’ [24].
Some argue that MAP has met both Koch’s postulates ([25],
Text S1) and Relman’s criteria [26] for microbial causation of
Crohn’s disease. MAP is present in pasteurized milk [27], infant
formula made from pasteurized milk [28], breast milk from
women with Crohn’s disease [29], surface water [30–32], soil [30],
cow manure ‘‘lagoons’’ that can leach into surface water [33], cow
manure in both solid and liquid forms that is applied as fertilizer to
agricultural land [33], and municipal tap water [25,34], providing
multiple routes of transmission to humans.
Yet, MAP is still not accepted as the cause of Crohn’s disease.
The identification of MAP by methods other than direct
visualization by light microscopy, and the identification of MAP
in small numbers by light microscopy, has not constituted
convincing evidence of causation to the medical community at
large. When MAP is not completely ignored as a cause of Crohn’s
disease [35], it is dismissed in part because of this lack of
visualization of large numbers of the organism ([36], Text S1):
Even advocates of the theory that MAP causes Crohn’s
disease concede that infection, if present, consists of a low
bacterial load …. [37]
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with Crohn’s disease, leading investigators to speculate that
these organisms are not present (or) the bacterial load is very
low …. [38]
Is it possible that large numbers of MAP are actually present in
some of the histologic (microscopic) lesions of patients with
Crohn’s disease? Current MAP researchers argue that MAP
infection in humans exists only in a paucibacillary form, i.e., only
small numbers of organisms are present in the histologic lesions
[36]. Instead, the lack of direct visualization of large numbers of
the organism in histologic sections of Crohn’s tissues might be due
to the fact that the organism has not been looked for in locations
where it might be present in large numbers. Where might MAP be
present in large numbers in patients with Crohn’s disease?
An analysis of the literature on the pathology of Crohn’s disease
and on possible MAP infection in Crohn’s patients leads to the
following conclusions. First, that some patients with Crohn’s disease
might have pluribacillary disease, i.e., they might have large
numbers of MAP organisms in some of their histologic lesions.
Second, that in addition to macrophages, MAP might directly infect
and replicate within two other cell types. MAP might infect and
replicate within endothelial cells, both the endothelial cells lining
lymph vessels and the endothelial cells lining blood vessels, and
MAPmight infectand replicate withinadipocytes orfatcells.Third,
MAP organisms might therefore be present in large numbers in the
following locations in patients with Crohn’s disease:
1. The blood vessels, lymph vessels (lymphatics), and lymph nodes
in the mesentery of affected bowel wall segments.
2. The mesentery itself, i.e., the adipocytes that fill the mesentery.
3. The walls of fistulas.
Do Some Patients with Crohn’s Disease Have
Pluribacillary MAP Infection?
The two major mycobacterial diseases of humans are
tuberculosis and leprosy. The presence of both Mycobacterium
tuberculosis and Mycobacterium leprae varies within histologic lesions,
from pluribacillary or multibacillary (having large numbers of
organisms within histologic lesions) to paucimicrobial or pauciba-
cillary (having small numbers of organisms within histologic lesions
or none at all [39,40]). If Crohn’s disease is, like M. tuberculosis and
M. leprae, caused by a mycobacterium [25], and if some humans
with other mycobacterial diseases have large numbers of the
causative organism in some of their histologic lesions, isn’t it
possible that some patients with Crohn’s disease might also have
large numbers of MAP in some of their histologic lesions, if only
the right lesions were examined?
The idea that some patients with Crohn’s disease might have
large numbers of MAP organisms in their tissues is supported by
correlation with both human M. leprae infection and bovine MAP
infection. The classic lepromatous form of leprosy demonstrates
large numbers of organisms in the histologic lesions, and
antibodies to M. leprae antigens in the blood [40]. Cattle with
Johne’s disease that have ‘‘multibacillary lesions tend to have high
serum antibody concentrations’’ [41], and humans with Crohn’s
disease have antibodies to MAP antigens in their blood. ELISA
studies, which detect antibodies to MAP antigens in the blood,
demonstrate that anywhere from 23% to almost 90% of Crohn’s
patients have such antibodies [11,15–17].
MAP is a mycobacterium. Other mycobacterial infections in
humans have some histologic lesions that contain large numbers of
the causative organism. If Crohn’s disease is caused by MAP, then
like other mycobacterial species that cause human disease, large
numbers of MAP organisms might be present in some of the
histologic lesions of Crohn’s disease, organisms that because of
their presence in large numbers could be easily seen under the
microscope (with the 406 objective rather than the 1006 oil
immersion objective [36]), if only we looked in the right places.
What Cell Types Might Be Infected by MAP in
Crohn’s Disease?
What is the fundamental pathologic problem in Crohn’s
disease? Most researchers argue that Crohn’s disease is a problem
of the intestinal epithelial cell. Some kind of defect in the intestinal
epithelium allows normal (or ‘‘commensal’’) gut bacteria through
the epithelium into the deeper bowel wall, setting up an
autoimmune response [35,42]. A careful reading of the literature
on the pathology of Crohn’s disease suggests that endothelial cells
and adipocytes rather than intestinal epithelial cells might
determine the unique pathologic features of Crohn’s disease.
The potential role of adipocytes in the pathology of Crohn’s
disease will be discussed later in this article. The following sections
will consider the role of endothelial cells. Endothelial cells line both
lymph vessels and blood vessels, forming the intima or inner layer
of these vessels along with a basement membrane. Since the term
‘‘vascular’’ is generally used to refer to blood vessels only,
endothelial cells lining blood vessels will be referred to as vascular
endothelial cells throughout this article, and endothelial cells lining
lymph vessels will be referred to as lymphatic endothelial cells.
The literature suggests that both lymphatic endothelial cells and
vascular endothelial cells proliferate in Crohn’s tissues. The
endothelial cells proliferate within already existing vessels, causing
obstruction within those vessels (and depending on whether vascular
or lymphatic, a lesser or greater propensity for granuloma formation),
and they proliferate and migrate, forming the basis of new blood
(neoangiogenesis) or lymphatic (lymphangiogenesis) vessels.
Does a Proliferating Lymphatic Endothelial Cell
Explain Some of the Pathologic Changes in
Crohn’s disease?
In a recent review article [43], Van Kruiningen and Colombel
present evidence that Crohn’s disease was historically considered
to be a chronic lymphangitis. They conclude that since Crohn’s
disease involves a chronic inflammation of lymphatic vessels, that
the endothelium lining these lymphatic vessels is the location
where the etiologic agent might be located. They list a variety of
bacteria and viruses that are known to directly infect lymphatic
endothelium [43].
Van Kruiningen and Colombel believe that the older articles
were describing a chronic lymphangitis, an inflammation of the
lymphatics, i.e., an infiltration of the lymphatic lumens or walls by
lymphocytes. A close reading of the early articles they cite,
however, reveals a different process. Instead of a chronic
inflammation of the lymphatics, there is a proliferation of
lymphatic endothelial cells in Crohn’s disease, resulting in focal
obstruction, including granuloma formation, and lymphangiecta-
sia, dilation of the vessels on either side of the obstruction.
Hadfield (1939) writes that the ‘‘affected germinal center was
entirely replaced by proliferating endothelial cells with weakly-
staining nuclei … in the midst of the cells constituting these
endothelial aggregates it was usually possible to identify a
Langhans’ giant cell … it became obvious that endothelial
proliferation continued in the giant cell system’’ [44].
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In the earliest stage, small foci of leukocytes closely
resembling the endothelial cells of lymphatics appear in
the lacteals of the lamina propria, between the glands and
the muscularis mucosae. These endothelial cells change
from flat to polygonal, with abundant eosinophil cytoplasm
and somewhat prominent hyperchromatic nuclei. Prolifer-
ation of these cells continues and finally blocks the
lymphatics [Figure 1]. In slightly later stages similar masses
of proliferating endothelium obstruct lymphatics in the
submucosa and subserosa…The reaction is sharply focal
and intervening stretches of the lymphatics are dilate-
d…Once the larger lymphatics become completely blocked
deep in the submucosa and subserosa as well as in the
lamina propria, eosinophils and then lymphoid cells
surround these endothelial masses …. The endothelial cells
become more closely massed and tend to coalesce, forming
giant cells. [45]
In both of the above descriptions, the swollen and proliferating
endothelial cells cause focal occlusions of the lymphatics within
which they lie. Shockingly to all current readers, who know
granulomas to be collections of modified macrophages, both
Warren and Sommers and Hadfield carefully describe the
transformation of these proliferating endothelial cells into
granulomas (Figure 2). They then describe the secondary
ulceration, fissures, and fistulas that are a consequence of the
primary process of lymphatic obstruction.
Neither of these older studies describes lymphangiogenesis, the
development of new lymphatic vessels from preexisting ones. A
recent study, however, describes a markedly increased density of
small lymphatic vessels in the submucosa of Crohn’s small intestine
resection specimens, and in ‘‘every layer of the bowel wall, except
in the lamina propria,’’ in colon resection specimens from Crohn’s
patients [46].
Does a Proliferating Vascular Endothelial Cell
Explain Some of the Pathologic Changes in
Crohn’s Disease?
The literature investigating the role of bowel wall or mucosal
layer blood vessels in the pathogenesis of Crohn’s disease provides
evidence of three vascular abnormalities in Crohn’s tissues:
1. injury to individual vascular endothelial cells, that might
represent the initial invasion of those cells by MAP,
2. diffuse proliferation of vascular endothelial cells within already
existing blood vessels, causing occlusion of those vessels but
only occasional granuloma formation, and
3. angiogenesis, also called neoangiogenesis or neovascular
proliferation, the development of new blood vessels, the result
of the proliferation and migration of vascular endothelial cells.
Recently, researchers have argued that Crohn’s disease is a
disease of the small blood vessels, the so-called microvasculature,
of the bowel wall [47]. There seem to be two problems with the
microvasculature. The first problem is specific defects in or
damage to individual vascular endothelial cells in the mucosal
layer of both Crohn’s disease and ulcerative colitis intestines. The
studies of Binion and colleagues, for example, demonstrate that
both Crohn’s disease and ulcerative colitis are characterized by
specific ‘‘acquired defects’’ of vascular endothelial cells lining post
capillary venules [48,49]. A study by Sankey and colleagues
describes three changes in mucosal blood vessels, two of which are
found in both Crohn’s disease and ulcerative colitis, and a third
rare ‘‘summit’’ lesion of the mucosal capillary wall that might be
unique to Crohn’s disease [50].
The second problem with the mucosal capillaries in both
Crohn’s disease and ulcerative colitis is an apparent tendency to
sprout new blood vessels. In addition to the studies of defects in or
damage to individual mucosal layer vascular endothelial cells, a
separate literature has developed suggesting that angiogenesis,
‘‘the process of new capillary formation from preexisting
vasculature in adult tissues’’ [51], is a component in the
development of Crohn’s disease and ulcerative colitis [51,52].
This pathologic angiogenesis is very carefully described in the
mucosa of both Crohn’s disease and ulcerative colitis. What
appears to be unique to Crohn’s disease is that this neovascular
proliferation is present not only in the mucosal layer but in the
deeper bowel wall as well. A study by Wakefield and colleagues
Figure 1. ‘‘Ileum in Chronic Cicatrizing Enteritis, Showing
Endothelial Cells Proliferating and Blocking a Submucosal
Lymphatic. Phosphotungstic Acid – Hematoxylin Stain. 6800’’
Reads the Original Legend for This Photograph. Note the need for
magnification greater than 6400 to accurately identify the cells as
endothelial cells. Large numbers of MAP organisms might be found in
these proliferating endothelial cells, before they become granulomas.
Very kindly reprinted from Am. J. Pathol. 1948, 24: 475–501 with
permission from the American Society for Investigative Pathology [45].
doi:10.1371/journal.ppat.1000234.g001
PLoS Pathogens | www.plospathogens.org 3 March 2009 | Volume 5 | Issue 3 | e1000234Figure 2. Three Photographs Illustrating Intralymphatic Granulomas. Photograph 35 shows the combination of occlusion by a granuloma
and accompanying lymphangiectasis. Photographs 36 and 37 show intralymphatic granulomas. The arrows (added by the author) point to the focal
origins of the granulomas in discrete segments of endothelial cells lining the lymphatic vessels. Large numbers of MAP organisms might be found in
these endothelial cells, rather than within the fully formed granulomas. Reprinted from Military Surgeon 1951, 109: 463–502, a publication of the
Armed Forces Institute of Pathology, with the very kind assistance of Dr. Leslie Sobin [75].
doi:10.1371/journal.ppat.1000234.g002
PLoS Pathogens | www.plospathogens.org 4 March 2009 | Volume 5 | Issue 3 | e1000234describes a ‘‘mesenteric granulomatous vasculitis’’ of intestines
affected by Crohn’s disease [53]. A careful reading of this study,
however, reveals that the blood vessels involved are not inflamed
and are not in the mesentery. There is occlusion of blood vessels,
by fibrin, with endothelial cell ‘‘prominence,’’ in the muscularis
propria. The vascular ‘‘injury’’ consists of ‘‘intense neovascular-
ization’’ in the submucosa and subserosa [53].
The current literature describes neoangiogenesis involving the
mucosal layer in both Crohn’s disease and ulcerative colitis, and
the single study just mentioned suggests the presence of
neoangiogenesis in the deeper bowel layers in Crohn’s disease.
In contrast, older literature describes occlusive changes in the
bowel wall in Crohn’s disease, including what is specifically
described as intimal proliferation, i.e., the proliferation of the
endothelial cells that constitute the intima. These older studies of
the vasculature in Crohn’s disease, like the earlier studies of the
lymphatic system, do not emphasize inflammation in the blood
vessels but rather ‘‘obliterative changes, including intimal
proliferation, subintimal fibrosis, medial hypertrophy, medial
fibrosis, and adventitial fibrosis, without significant inflammatory
cell component’’ ([54], emphasis added). For example, Van Patter
and colleagues (1954) write: ‘‘Localized and diffuse changes in
both arteries and veins of the bowel wall were encountered.
Thickening of the intima, both cellular and acellular, was more
prominent in the arteries than in the veins’’ [55]. They note
specifically that ‘‘[i]dentical changes in the intima of blood vessels
of tuberculous cattle have been reported … to follow intradermal
injection of tuberculin’’ that the accompanying figures describe as
a‘ ‘ proliferative endarteritis’’ ([55], emphasis added). This diffuse,
circumferential proliferation of vascular endothelial cells is so thick
as to completely occlude the lumen of the blood vessel.
While intimal proliferation is the most common description of
the changes within blood vessels, occasional granuloma formation
within blood vessels is also noted. Geller and Cohen [54] describe
vessels where both diffuse intimal proliferation and granuloma
formation occur together. ‘‘[I]ntimal-medial hypertrophy was also
noted …. These specimens demonstrated granulomatous involve-
ment of a vessel with obvious interruption of the internal elastic
lamina.’’ One of their figures is a ‘‘granulomatous inflammation
involv[ing] adventitia, media, and proliferated intima’’ [54]. One
of the more recent granuloma studies [56] also mentions the
occasional granuloma occluding subserosal arterioles.
The literature suggests that the proliferation of lymphatic
endothelial cells in Crohn’s disease occurs primarily within already
existing vessels and is focal or segmental (Figure 2) rather than
diffuse or circumferential, causing granuloma formation that
obstructs the vessel and lymphangiectasis, and only secondarily
causing lymphangiogenesis. In contrast, the proliferation of
vascular endothelial cells in Crohn’s disease appears equally likely
to cause both neoangiogenesis, the development of new blood
vessels, and circumferential thickening of the intima within already
existing blood vessels (Figure 3), but only occasional granuloma
formation.
What Causes Endothelial Cells to Proliferate in
Crohn’s Disease?
If proliferating endothelial cells are the basis of the pathologic
changes in Crohn’s disease, what causes them to proliferate? If
MAP causes Crohn’s disease, then direct infection of endothelial
cells by MAP might be the reason that endothelial cells proliferate
in Crohn’s disease.
Can MAP directly invade (or ‘‘infect’’) endothelial cells? MAP in
dairy cattle with Johne’s disease are engulfed by subepithelial
macrophages that then ‘‘migrate into local lymphatics, spreading
the infection to regional lymph nodes’’ [57]. It is not known
whether MAP can directly infect the endothelial cells lining the
lymphatics within which the macrophages travel. ‘‘There is little
known about where exactly viable MAP can be found in human
tissues or, since most pathogenic Mycobacteria are intracellular, in
which cells MAP can live and grow in humans. While the site of
infection and tissue pathologies of MAP in animals can be assessed
at necropsy, there is enough dissimilarity between digestive
processes of ruminants and humans that this information may
not necessarily inform studies in humans’’ [58].
Other Mycobacterium species, however, are known to infect and
replicate within endothelial cells. Mycobacterium tuberculosis can
infect and replicate within vascular endothelial cells [59], and
Mycobacterium leprae can infect and replicate within both vascular
and lymphatic endothelial cells [60].
Does the invasion of endothelial cells by microorganisms cause
them to proliferate? Recent evidence that ‘‘indigenous’’ microbes
Figure 3. This Photograph of ‘‘Obliterative Endarteritis’’
Illustrates the Diffuse Endothelial Cell Proliferation within
Blood Vessels, Causing the Circumferential Widening of the
Intima, in Contrast to the Focal Proliferation of Endothelial
Cells within Lymphatics, Resulting in Granulomas. Large
numbers of MAP organisms might be found within the endothelial
cells of the thickened intima. Reprinted from Military Surgeon 1951,
109: 463–502, a publication of the Armed Forces Institute of Pathology,
with the very kind assistance of Dr. Leslie Sobin [75].
doi:10.1371/journal.ppat.1000234.g003
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angiogenesis, and Bartonella species can both infect endothelial
cells and stimulate angiogenesis [63], suggests that angiogenesis or
lymphangiogenesis, the neovascular proliferation of endothelial
cells, is a possible mechanism whereby MAP establishes chronic
infection.
So Where Are All the MAP in Patients with Crohn’s
Disease?
If some patients with Crohn’s disease might have pluribacillary
MAP infection, i.e., if some of their histologic lesions might have
large numbers of MAP organisms, and if MAP might be present
within endothelial cells lining lymphatic and vascular walls, then
two kinds of places where no one has yet looked for them by either
direct or indirect methods might have abundant MAP organ-
isms—places where there are large blood vessels or lymphatics and
places where there many small blood vessels or lymphatics.
Where are large blood vessels or lymphatics where abundant
MAP organisms might be located? The large blood vessels and
lymphatics that supply and drain the intestines are in their
attached mesentery. These mesenteric blood vessels and lymphat-
ics, located outside of the bowel wall, might have large numbers of
MAP organisms.
Where are collections of small lymph or blood vessels where large
numbers of MAP organisms might be located? The fistulas of
patients with Crohn’s disease, whose walls are usually described as
being composed of capillaries (i.e., small blood vessels) but might
instead be small lymphatic channels as discussed below, are a unique
location where large numbers of MAP organisms might be found.
The Evidence for Lymphatics in the Mesentery as
a Possible Site of Large Numbers of MAP
Organisms in Crohn’s Disease
The evidence is strongest that the endothelial cells lining the
walls of mesenteric lymphatics are a possible site of large numbers
of MAP organisms in Crohn’s tissues. The early histopathologic
studies of ‘‘regional ileitis’’ [45], the drainage studies of the
lymphatics during surgery [64,65], and mesenteric lymphatic
complications of Crohn’s disease [66] all suggest that the
mesenteric lymphatics are obstructed adjacent to the segments of
intestine affected by Crohn’s disease. Additionally, the only animal
model that closely matches the features of Crohn’s disease was
produced by injecting formalin into the mesenteric lymph nodes
draining the terminal ileums of pigs, producing obstruction of the
mesenteric lymphatics draining from those lymph nodes [67].
One feature that is unique in human pathology to Crohn’s
disease is ‘‘creeping fat’’ or ‘‘fat wrapping,’’ where the mesenteric
fat wraps around the bowel wall of intestinal segments affected by
Crohn’s disease (see discussion below). Another phenomenon, the
development of fistulas (also discussed below), while not completely
unique to Crohn’s disease, does distinguish Crohn’s disease from
ulcerative colitis. This porcine model of Crohn’s disease is unique
to all animal models of bowel inflammation in that the pigs
developed fistulas, and while the ‘‘wrapping phenomena typical of
Crohn’s disease was not present in (the) animals, probably due to
the short follow-up time,’’ the mesentery was ‘‘oedematous’’ and
‘‘clearly thickened’’ [67]. No other animal model of Crohn’s
disease has produced fistulas in the affected animals or produced
anything close to the mesenteric creeping fat in Crohn’s disease.
In this porcine model, the destroyed lymph nodes were
equivalent to the focal obstruction of the lymphatic vessels in
Crohn’s disease caused by proliferating endothelial cells. There
was lymphangiectasia in the bowel wall and in the mesentery on
either side of the obstructed lymph nodes, as there is lymphan-
giectasia on either side of the focal proliferations of endothelial
cells in the lymphatics in Crohn’s tissues. There were granuloma-
like formations (although tubular rather than round) in the
subserosa and mesentery in the pigs. This study reproduced every
pathologic feature of Crohn’s disease [67].
Other studies show that the obstruction of mesenteric lymphatics
in Crohn’s disease correlates with the pathologic alterations in the
mucosaanddeeperbowelwall.VanKruiningenandColombel[43]
describe a series of studies by Tonelli [68] that make the same
argument for mesenteric lymphatics that Wakefield and colleagues
make for mesenteric blood vessels as described below—that the
mucosal ulcers along the mesenteric border in Crohn’s disease
correlate with the lymphatic drainage into the mesentery. In
addition, according to Van Kruiningen and Colombel [43], Tonelli
argues that the differing lengths of the lymphatics draining the
jejunum and ileum are correlated with the differing lengths of the
linear ulcers in Crohn’s disease. Shorter vasa recta lymphatics drain
the jejunum; the linear ulcers in the jejunum are short. Longer vasa
recta lymphatics drain the ileum; the linear ulcers in the ileum are
long. This contrasts with the vasa recta arterial supply to the
intestines, where the vasa recta arteries supplying the jejunum are
long, and those supplying the ileum are short.
As discussed above, the older literature strongly suggests that the
lymphatics are the primary site of granuloma formation and that
this will be the case in the mesenteric lymphatics as it is in the bowel
wall lymphatics. The literature also suggests that the lymphatic
vessels in the mesentery respond to obstruction by lymphangiectasia
rather than lymphangiogenesis. The literature to date does not
support the idea of a large vessel lymphangiogenesis in the
mesentery. Instead, lymphatic obstruction and lymphangiectasia
are the probable pathologic processes in the mesenteric lymphatics.
The Evidence for Blood Vessels in the Mesentery
as a Possible Site of Large Numbers of MAP
Organisms in Crohn’s Disease
As described above, there is both occlusion of already existing
blood vessels and neoangiogenesis in the bowel wall in Crohn’s
disease. Is there evidence of both occlusion of already existing blood
vessels and neoangiogenesis in the mesentery in Crohn’s disease?
There is evidence that ischemia in general (constriction or
occlusion of blood vessels) is involved in the pathogenesis of
Crohn’s disease. For example, smoking, which increases the risk of
ischemic events in a variety of vascular beds, increases the risk of
Crohn’s disease and worsens its severity and course in already
affected patients [69,70]. The differential diagnosis of Crohn’s
disease includes ischemic injury of the mesenteric arteries because
ischemic occlusion of the mesenteric arteries is known to produce a
pattern of injury with clearly defined margins, just as Crohn’s
disease is characterized by discrete segments of diseased bowel
with intervening segments of normal intestine [71]. On the other
hand, patients with bleeding disorders such as hemophilia and
Von Willebrand disease have a decreased risk of developing
Crohn’s disease [47]. There are case studies of treating Crohn’s
disease by the administration of heparin [47].
The vasa recta arteries in the mesentery just outside the bowel
wall are the most likely blood vessels in the mesentery to find
abundant MAP organisms. These vasa recta arteries begin in the
mesentery, as branches off of the terminal arcades. They enter the
bowel wall in the subserosa, either as ‘‘short’’ branches off of the
‘‘long’’ vasa recta on the mesenteric side of the bowel wall, or as
continuations of the long vasa recta that course around the
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teric side of the bowel wall [72]. They are the most likely place to
find abundant MAP organisms because occlusion of these specific
arteries would be most likely to produce the sharply demarcated
mucosal lesions of Crohn’s disease.
As described above, the linear ulcers in Crohn’s disease lie along
the mesenteric attachment, i.e., where the mesentery first connects
with the bowel wall, whether these ulcers are in the jejunum,
ileum, or colon. In animal models [73,74] and postmortem
examination of normal bowel anatomy [72], Wakefield and
colleagues demonstrate that the short branches of the vasa recta of
the jejunum, ileum, and colon are all end arteries, i.e., they did not
anastomose with other vessels in the submucosal plexus once they
reach the submucosa, whereas the long vasa recta entering the
bowel on the antimesenteric side do anastomose with other vessels
once they reach the submucosa. They conclude that occlusion, in
the mesentery, of the mesenteric side short vasa recta in patients
with Crohn’s disease would produce the mesenteric side and
longitudinal (parallel to the mesentery) mucosal ulcers character-
istic of Crohn’s disease [72].
As just described, there is evidence that, if the mesenteric vasa
recta arteries in Crohn’s disease were occluded, then this occlusion
would likely cause the transmural ulcers seen in Crohn’s disease.
But has anyone looked at the arteries in the mesentery of Crohn’s
intestines under the light microscope? Only older studies have
included examination of mesenteric blood vessels in Crohn’s
patients, and these older studies only mention the mesenteric
blood vessels in passing. Rappaport and coworkers (1951) [75]
state: ‘‘Vascular changes such as chronic phlebitis and obliterating
endarteritis [Figure 3] were more prominent in the mesentery and
the serosa than in any of the other coats.’’ Knutson and coworkers
(1968) [76] described their obliterative vascular changes in fully
developed Crohn’s disease as being ‘‘numerous both in the
submucosa and periintestinal fat.’’
There is slight histologic evidence and similarities to other
ischemic conditions, suggesting that mesenteric vasa recta
occlusion occurs in Crohn’s disease. Is there evidence of
mesenteric angiogenesis in Crohn’s disease?
A series of older angiographic studies show a specific pattern of
what appears to be a proliferation of large blood vessels in the
mesentery of Crohn’s disease–affected intestines [77–79]. These
studies show that the density of both long and short vasa recta are
increased to the segments of intestine affected by Crohn’s disease,
whereas the vasa recta density is normal to the non-affected
intestinal segments in Crohn’s patients. Brahme and Lindstro ¨m
(1970) [77] write: ‘‘The mesenteric arteries were not noticeably
widened, but the number of arteriae rectae supplying the involved
area appeared increased …. In small-bowel lesions about 1.2–2.0
such arteries originated per centimeter, which was more than twice
the frequency found in normal specimens.’’ Kalima and colleagues
(1975) [78] write: ‘‘The long vasa recta branched from the marginal
arcades as in the normal ileum, but the distances between these
arteries as they ran in parallel towards the antimesenteric border of
the gut were much narrower than in normal ileum. So the number
oflongvasarectawasmarkedly(3–5times)increasedperunit length
of ileum.’’ Brahme and Hildell (1976) [79] write: ‘‘The arteriae
rectae longae … were numerically increased in 74 of 115 lesions of
the small bowel (64%) and in 28 of 55 colonic lesions (51%).’’
The literature suggests that there is both occlusion of already
existing vasa recta arteries and neoangiogenesis of the vasa recta
arteries in the mesentery attached to segments of intestine affected
by Crohn’s disease, and that the endothelial cells constituting the
intima of these occluded and proliferated blood vessels might
contain large numbers of MAP organisms.
The Evidence for Fistulas in Crohn’s Patients as a
Possible Site of Large Numbers of MAP Organisms
Fistulas are tracts or communications between anatomically
distinct sites that do not normally communicate with each other.
The fistulas in Crohn’s disease begin in the bowel and end in other
sections of the bowel (entero-enteric), in other organs (e.g.,
rectovaginal), or on the skin surface (entero-cutaneous).
The walls of fistulas are always described as being composed of
‘‘granulation tissue’’ [80,81]. What is granulation tissue but a mass
of capillaries, or small blood vessels? Granulation tissue is part of
how the body responds to wounds. Granulation tissue is
physiologic angiogenesis [71].
In Crohn’s fistulas, however, this granulation tissue, this mass of
small blood vessels, is usually permanent [81]. Is the ‘‘granulation
tissue’’ in fistulas actually neoangiogenesis, the result of the
neovascular proliferation of endothelial cells? Neoangiogenesis
affects all of the layers of the bowel wall in Crohn’s disease and, as
just discussed, might be present in the mesentery as well. Are the
small capillaries that compose the walls of fistulas a result of the
process of neoangiogenesis in Crohn’s disease? The new vessels
appear to begin in the mucosa and track along the course of the
original vessels into and through the bowel wall.
The known association between various cancers and angiogen-
esis [82] supports the idea that fistulas are the result of a process of
neoangiogenesis. Cancers are a known cause of fistula formation.
Are the fistulas caused by cancer also a result of the process of
neoangiogenesis?
As mentioned above, lymphangiogenesis has recently been
described in the bowel wall in Crohn’s patients [46]. It is possible
that the walls of fistulas are actually composed of small lymphatic
vessels rather than small blood vessels. The same process of
formation of these small lymphatics in the mucosa, and tracking
along the course of the original lymphatics into and through the
bowel wall, could also cause fistula formation.
The characteristic fistulas of Crohn’s disease might be caused by
the proliferation and migration of endothelial cells, resulting in
neoangiogenesis or lymphangiogenesis, that as discussed previous-
ly have been observed in the mucosa, deeper bowel wall, and
mesentery in Crohn’s patients. Since these fistulas are composed of
small vessels lined by endothelial cells, whether of lymphatic or
vascular origin, fistulas might be a site of large numbers of MAP
organisms in patients with Crohn’s disease.
Where Else Are All the MAP in Patients with
Crohn’s Disease? The Evidence for the Mesenteric
Fat as a Possible Site of Large Numbers of MAP
Organisms
As mentioned above, ‘‘creeping fat’’ is the phenomenon whereby
the mesenteric fat attached to segments of intestine affected by
Crohn’s disease thickens, stiffens, and wraps around the bowel wall
[83]. Creeping fat is absolutely unique in human pathology to
Crohn’s disease [84].There is no otherdisease inhumanswhere the
mesenteric fat wraps around the bowel wall. Creeping fat is,
however, present in dairy cows with Johne’s disease [85].
Despite the singularity of mesenteric creeping fat in human
pathology, there is a paucity of literature devoted to the subject
[83]. Two lines of evidence, however, suggest that the mesenteric
fat attached to Crohn’s affected segments of intestine is a possible
site of large numbers of MAP organisms.
The first line of evidence is the similarity of adipocytes to
macrophages [86]. This similarity extends to the ability of
adipocytes to be infected by microorganisms, including the parasite
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In particular, the adipocytes in the mesentery ‘‘might be a main
reservoir of bacteria’’ [83]. MAP is known to infect macrophages
[57]. Do the similarities between macrophages and adipocytes
extend to the ease with which MAP can invade them?
The second line of evidence is the apparent proliferation of
adipocytes in the creeping fat. Creeping fat is usually described as a
hypertrophy of the mesenteric fat. But while there is a hypertrophy,
an increase in size, of the mesentery as a whole, there is actually a
hyperplasia,anincreaseinnumber,ofthe individualadipocytesthat
comprise the mesentery [83,89]. This hyperplasia of adipocytes
might also be described as a proliferation of the adipocytes, similar
to the proliferation of endothelial cells that is present in the
lymphatics and vasculature in Crohn’s intestines. Desruisseaux and
colleagues note specifically that ‘‘with certain types of adenoviruses,
infection with viral particles leads to long-term hyperplasia and
hyperproliferation of adipocytes’’ [87]. Does infection of mesenteric
adipocytes by MAP cause them to proliferate, causing the creeping
fat that is absolutely unique among human diseases to Crohn’s
disease, but shared by dairy cows with Johne’s disease?
Why Haven’t Large Numbers of MAP Organisms
Already Been Found in the Mesentery—in the
Lymph Nodes?
One place in the mesentery has been investigated for MAP: the
lymph nodes. The earliest descriptions of Crohn’s disease carefully
noted that the lymph nodes in the mesentery are often enlarged and,
irrespective of their size, often contain the same type of giant cell
granulomas found in the bowel wall [90,91]. The mesenteric lymph
nodes from Crohn’s patients were in the early days carefully
examined for Mycobacterium tuberculosis, not MAP, and the lack of
identification of M. tuberculosis in the Crohn’s nodes was one of the
characteristics that distinguished Crohn’s disease from ileocecal
tuberculosis.
As detailed by Chiodini, attempts were made to culture
mycobacteria other than tuberculosis from Crohn’s tissues,
including mesenteric lymph nodes, beginning in the late 1970s
[92]. In the modern era, a single mesenteric lymph node has been
investigated for the presence of, and found to contain, MAP [93].
Why then haven’t large numbers of MAP been found in the
mesenteric lymph nodes of patients with Crohn’s disease?
There are two possible reasons that large numbers of MAP
organisms have not been found in the mesenteric lymph nodes.
The first reason is that no one has looked very hard. Surprisingly,
with the exceptions just noted, there have been no studies
investigating mesenteric lymph nodes from patients with Crohn’s
disease for the presence of MAP by the wide variety of direct and
indirect methods currently available [94].
The second possible reason that large numbers of MAP
organisms have not been found in the mesenteric lymph nodes
is that the wrong nodes might have examined. Only lymph nodes
containing granulomas have been examined, and granulomas
might not be the site of large numbers of MAP organisms.
Why the Granulomas in Crohn’s Tissues Might Not
Be the Site of Large Numbers of MAP Organisms,
and Where Exactly Large Numbers Might Instead
Be Found
Granulomas are usually described as a reaction to foreign
antigen, with the antigen, whether microbiologic or otherwise,
being found within the granuloma. Since the etiologic agent of
Crohn’s disease is assumed to be within the granuloma,
investigators have focused their attention on determining exactly
where the granulomas are in the bowel wall in Crohn’s intestines
[56,95,96], and attempting, rarely successfully, to identify small
numbers of MAP from the granulomas in the bowel wall [97].
If specific etiologic agents cause granulomas, and those specific
etiologic agents are usually within the granulomas, why haven’t
large numbers of MAP organisms been found within Crohn’s
granulomas? The probable reason is that Crohn’s granulomas are
formed from no longer proliferating endothelial cells, and large
numbers of MAP organisms will probably be present within
proliferating endothelial cells instead.
Warren and Sommers write: ‘‘Once the larger lymphatics
become completely blocked deep in the submucosa and subserosa
as well as in the lamina propria, eosinophils and then lymphoid cells
surround these endothelial masses in increasing numbers. The
endothelial cells become more closely massed and tend to coalesce,
forming giant cells. Incomplete stages inthisprocess canbe found in
which individual endothelial cells are partly fused’’ [45]. Hadfield is
more explicit. He writes: ‘‘[I]t became obvious that endothelial
proliferation continued in the giant-cell system until it eventually
reacheda maximal diameterofapproximately fourto five times that
of the germinalcentre which it had replaced …. When the giant-cell
system has reached this size, cell proliferation apparently ceases’’
[44]. These descriptions suggest that granulomas, since they are
formed from massed, coalescing but no longer proliferating
endothelial cells, will not have large numbers of MAP within them.
If large numbers of MAP organisms won’t be found within
granulomas, where exactly will they be found? In their classic
textbook [71], Cotran and colleagues describe a granuloma as
follows: ‘‘A granuloma … consists of a microscopic aggregation of
macrophages that are transformed into epithelium-like cells sur-
rounded by a collar of mononuclear leukocytes, principally
lymphocytes and occasionally plasma cells.’’ There are two
components to a granuloma, a collection of epithelium-like cells,
and a surrounding collar of mononuclear leukocytes. Large numbers
of MAP organisms might be found in the collections of (not
macrophages but) endothelial cells, just before they become
‘‘transformed into epithelium-like cells’’ and are surrounded by a
‘‘collar of mononuclear phagocytes.’’
Regarding the mesenteric lymph nodes, this means that large
numbers of MAP organisms might be found in the lymph nodes
that were described in the older literature as hyperplastic rather
than granulomatous, a hyperplasia of what might be proliferating
endothelial cells rather than lymphocytes. Van Patter and
colleagues note that in the mesenteric lymph nodes in their
Crohn’s specimens, ‘‘[t]he endothelial cells of the sinusoids had
undergone proliferation but the process was more generalized than
in the lymphatics. The endothelial cells (phagocytes) occurred in
large numbers in the dilated lymph channels’’ [55]. Mesenteric
lymph nodes might have large numbers of MAP organisms during
this phase of endothelial cell proliferation, before that proliferation
ceases, when the ‘‘maximal diameter’’ of the mass of proliferating
endothelial cells is reached, but before the endothelial cells stop
proliferating, are transformed into epithelium-like cells, and are
surrounded by a collar of mononuclear phagocytes.
A situation similar to the mesenteric lymph nodes might be the
case in the mesenteric lymphatics. Large numbers of MAP
organisms might be found not in fully formed granulomas but in
the masses of proliferating endothelial cells just before they become
granulomas (Figure 1). Large numbers of MAP might also be found
in the segments of proliferating endothelial cells along the walls of
the lymphatics adjacent to granulomas, which appear to be the
source of the endothelial cells forming the granulomas (Figure 2).
Since the literature suggests that the mesenteric vasculature
won’t contain many granulomas, large numbers of MAP
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walls of the vasa recta arteries that are ‘‘increased in number’’ in
the mesentery attached to Crohn’s disease–affected segments of
intestine, and within the circumferentially proliferating endothelial
cells lining (and obstructing) already existing vasa recta arteries in
that same mesentery (Figure 3).
What Are the Other Obstacles to Finding Large
Numbers of MAP Organisms in the Tissues of
Patients with Crohn’s Disease?
In addition to what might be the wasted effort trying to find
large numbers of MAP within the granulomas in Crohn’s tissues,
several other obstacles might prevent the direct visualization of
large numbers of MAP organisms in the histologic lesions of
patients with Crohn’s disease. One major obstacle is that all of the
‘‘immunosuppressive’’ drugs used to treat Crohn’s disease might
have anti-MAP activity.
The use of steroids in Crohn’s disease and other immuno-
suppressive therapy are considered contraindicated in
pulmonary tuberculosis, exacerbating the disease. However,
the detrimental effects of immunosuppressive drugs on
mycobacterial infections are not as pronounced as believed.
Steroids in combination with antimicrobial agents have been
used for treatment of leprosy and in tuberculosis and other
mycobacterial infections …. Studies in cattle with paratu-
berculosis have shown that massive corticosteroid adminis-
tration does not significantly influence the clinical manifes-
tations or outcome of the disease, although it was expected
to. Treatment of experimental M. paratuberculosis infection in
rabbits with methotrexate, a powerful immunosuppressive
drug, resulted in clinical improvement even though the
bacillary load increased. [92]
In addition to steroids, many of the drugs used to treat Crohn’s
disease might actually act by inhibiting MAP. Methotrexate [98],
6-mercaptopurine [98], the 5-amino-salicylic acid portion of
sulfasalazine [99], cyclosporine A [100], rapamycin [100], and
tacrolimus [100] all inhibit the growth of MAP in vitro. Since
many current patients with Crohn’s disease have been or are
undergoing treatment with one of more of these drugs at the time
of their surgery, both the modern histopathology of Crohn’s
disease and the number of MAP organisms within biopsy or
resection specimens from Crohn’s patients may be quite different
from untreated cases. The ideal surgical specimen to test the
proposed hypothesis will therefore come from patients whose
Crohn’s disease is first diagnosed at the time of surgery.
Another obstacle to finding large numbers of MAP organisms in
tissues affected by Crohn’s disease is the possibility that the MAP
organism might be present in a cell wall–deficient or spheroplastic
form [101,102], a form that will not stain with traditional cell
wall–based acid fast (Ziehl-Neelsen or rhodamine-auramine)
stains. Immunohistochemical stains (directed against various
cellular antigens, usually proteins) [103], DNA in-situ hybridiza-
tion (utilizing a stretch of DNA or RNA against the complemen-
tary DNA or RNA in the organism) [12,18–21], or PCR
amplification of the IS900 DNA sequence specific for MAP [3–
5,6–14] might therefore be necessary to identify MAP organisms.
Another obstacle to finding large numbers of MAP organisms in
the tissues of patients with Crohn’s disease is that large numbers of
MAP organisms might not be present. It is of course entirely
possible that MAP infection in humans exists only in a
paucibacillary form, and so only ‘‘rare or no’’ organisms will be
present in the mesentery or fistulas.
Finally, while the author thinks it unlikely that a never before
identified organism might be the cause of Crohn’s disease, silver
staining seems a particularly useful histochemical technique for the
visualization of bacteria, and it has never been tested on Crohn’s
tissues. Tropheryma whippelii, the causative agent of Whipple’s
disease, while usually visualized by PAS (periodic acid Schiff)
staining, was seen in ‘‘great numbers’’ in the silver-stained section
of a lymph node in the original report [104]. The organism that
causes cat scratch disease, Bartonella henselae, was not seen under the
microscope until researchers finally thought to try the Warthin-
Starry silver stain on diseased lymph nodes [105], over 30 years
after the disease was first described. While now ‘‘easily’’ seen by
the usual H & E stain, Helicobacter pylori organisms were visualized
by the Warthin-Starry silver stain in Warren and Marshall’s first
report [106]. The many histochemical stains available for
microorganisms [107] do not appear to have been tested in the
intestines of patients with Crohn’s disease or anywhere else.
Conclusion
Demonstrating large numbersof MAP organismsinthemesenteric
fat, the blood vessels or lymphatics running through the mesenteric
fat, the hyperplastic (probably not granulomatous)lymph nodes in the
mesenteric fat, or the fistulas from patients with Crohn’s disease will
help establish that MAP causes Crohn’s disease. While fistulectomies
are a lastresort in patients with Crohn’sdisease, preliminaryresearch
can be performed on more readily available mesenteric fat attached
to resected segments of intestine. The author is severely disabled by
irreversible complications of Crohn’s disease and is unable to test the
ideas presented in this article. She reminds microbiologists,
pathologists, surgeons, and other scientists and physicians in training
that Barry Marshall was an internal medicine fellow when he and
pathologist Robin Warren published observations of the direct
visualization of H. pylori organisms in gastric biopsies [106]. The first
step in establishing that a bacterium causes a disease is the consistent
direct visualization of the organism by light microscopy ‘‘in such
numbers, and … in such a manner as to explain the lesions of the
disease’’ [108]. Let’s take that first step.
Dedicated to the memory of Rodger C. Haggitt, M.D.
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